Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.60 |
| ▸ | CTSC | P53634 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 12/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.57 |
| ▸ | GHSR | Q92847 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988893 | 0.91 | ACE (0.61) | ACEECE1ERAP2MAGI3GHSR | |
| SCHEMBL30051305 | 0.91 | ACE (0.72) | ACECTSCECE1ERAP2 | |
| Valyltryptophan SCHEMBL30821963 | 0.89 | ACE (0.75) | ACECTSCECE1 | |
| Valyltryptophan SCHEMBL29365770 | 0.89 | ACE (0.75) | ACECTSCECE1 | |
| Valyltryptophan SCHEMBL30821897 | 0.89 | ACE (0.75) | ACECTSCECE1 | |
| Valyltryptophan SCHEMBL150533 | 0.89 | ACE (0.75) | ACECTSCECE1 | |
| Valyltryptophan SCHEMBL150532 | 0.89 | ACE (0.75) | ACECTSCECE1 | |
| SCHEMBL1711338 | 0.88 | GHSR (0.64) | ACECTSCECE1ERAP2GHSR | |
| SCHEMBL30052446 | 0.88 | ACE (0.59) | ACECTSCECE1ERAP2 | |
| SCHEMBL1711224 | 0.88 | GHSR (0.64) | ACECTSCECE1ERAP2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113881680-B | T cell antigen receptor, multimeric complex thereof, and preparation method and application thereof | 华夏英泰（北京）生物技术有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12618082-B2 | Engineered muscle targeting compositions | THE BROAD INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12503493-B2 | Rabbit haemorrhagic disease virus (RHDV) vaccines | VST LLC (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250269065-A1 | B-CELL LYMPHOMA 2-ASSOCIATED ANTHANOGENE 3 (BAG3) GENE THERAPY USING AAV VECTOR | SPACECRAFT SEVEN, LLC (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025128817-A1 | ARTIFICIAL MICRORNAS TARGETING TAU | GENZYME CORPORATION (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-115418362-B | Co-immobilized enzyme, preparation method and application thereof | 吉林凯莱英医药化学有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025122559-A1 | CELL TYPE SPECIFIC ENHANCERS, METHODS AND USES RELATED THERETO | THE BROAD INSTITUTE, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-119823289-B | Protein-based biological material and preparation method and application thereof | 内蒙古和讯生物科技有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-113710807-B | Microorganisms and methods for producing oxygenates from hexoses | 布拉斯科公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-112703198-B | Methods and compositions for delivering agents across the blood brain barrier | 布里格姆妇女医院 | 2025-05-30 | — | — | CN | disclosed |
| CN-114072512-A | Sterile gene and related construct and application thereof | 未名生物农业集团有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-111303279-B | Single-domain antibody for novel coronavirus and application thereof | 北京凯因科技股份有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-111411097-B | Cyclodextrin glucosyltransferase mutant S90G | 江南大学 | 2022-02-15 | — | — | CN | disclosed |
| CN-114008197-A | Metabolic engineering for simultaneous consumption of xylose and glucose to produce chemicals from second generation sugars | 布拉斯科公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008069-A | Compositions of exosomes and AAV | 科迪亚克生物科学公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114007637-A | Recombinant factor VIII-FC for treatment of hemophilia and low bone mineral density | 比奥维拉迪维治疗股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113993552-A | Adeno-associated virus vector formulations and methods | 再生生物股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2022020616-A1 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | THE BROAD INSTITUTE, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| CN-113957061-A | Administration of kynurenine depleting enzymes for tumor therapy | 得克萨斯大学体系董事会 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618082-B2 | Engineered muscle targeting compositions | MUSK, MYO3B, MYOF | ACE 1346/4885CTSC 3026/4885ECE1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.